C4X Discovery to receive milestone payment for NRF2 exclusive worldwide license agreement

{
  "signal_id": "f5d515c4-6391-3f42-d76f-ca80f15a0358",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-09-04T07:00:00+00:00",
  "company": {
    "name": "AstraZeneca",
    "domain": "astrazeneca.com"
  },
  "data": {
    "url": "https://www.globenewswire.com/news-release/2026/09/04/3356390/0/en/c4x-discovery-to-receive-milestone-payment-for-nrf2-exclusive-worldwide-license-agreement.html",
    "title": "C4X Discovery to receive milestone payment for NRF2 exclusive worldwide license agreement",
    "excerpt": "4 September 2026 – C4X Discovery Holdings Ltd (“C4XD”), a pioneering Drug Discovery company, today announces that it will receive a $13 million milestone payment from AstraZeneca [LON: AZN], triggered by the entry of the oral NRF2 activator programme into the clinic. Under the terms of the licensing agreement announced in November 2022 , C4XD is potentially eligible to receive up to $400 million in preclinical, clinical development and commercial milestones, and to tiered mid-single digit royalties on future sales. AstraZeneca is advancing AZD4916, an oral NRF2 activator from the programme licensed from C4XD, in a Phase I study in healthy volunteers. The programme is being developed for the treatment of inflammatory and respiratory diseases. Nick Ray, CSO of C4X Discovery, said: “We are delighted to see the NRF2 activator programme progressing into the clinic. This is a testament to the work done by the AstraZeneca team on this very challenging target and moves the field a step closer to evaluating the potential of potent and selective NRF2 activators in a range of inflammatory diseases.” Emma Blaney, CEO of C4X Discovery, said : “This milestone further validates the C4XD team’s ability to deliver candidate-quality molecules for a range of challenging targets across the spectrum of inflammatory disease. We have also made significant progress in our α4β7 and PAD4 programmes...",
    "product": "AZD4916",
    "summary": "AstraZeneca is advancing AZD4916, an oral NRF2 activator licensed from C4X Discovery, into a Phase I study for the treatment of inflammatory and respiratory diseases.",
    "planning": false,
    "image_url": "https://ml-eu.globenewswire.com/Resource/Download/4cbafb93-20a9-4f19-ab37-19c8ddda1e21",
    "confidence": 0.9,
    "product_data": {
      "name": "AZD4916",
      "full_text": "AZD4916, an oral NRF2 activator",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-09-04T07:00:00Z",
    "article_sentence": "AstraZeneca is advancing AZD4916, an oral NRF2 activator from the programme licensed from C4XD, in a Phase I study in healthy volunteers.",
    "related_company_name": "C4X Discovery",
    "related_company_domain": "c4xdiscovery.com"
  }
}

curl https://signals.autobound.ai/v1/signals/f5d515c4-6391-3f42-d76f-ca80f15a0358 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"astrazeneca.com","limit":20}'